Axsome Therapeutics (AXSM) Revenue & Revenue Breakdown
Axsome Therapeutics Revenue Highlights
Latest Revenue (Y)
$270.60M
Latest Revenue (Q)
$87.17M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Axsome Therapeutics Revenue by Period
Axsome Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $270.60M | 440.80% |
2022-12-31 | $50.04M | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | - |
Axsome Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $87.17M | 16.22% |
2024-03-31 | $75.00M | 4.85% |
2023-12-31 | $71.53M | 23.77% |
2023-09-30 | $57.79M | 23.76% |
2023-06-30 | $46.70M | -50.62% |
2023-03-31 | $94.58M | 288.06% |
2022-12-31 | $24.37M | 44.67% |
2022-09-30 | $16.85M | 91.00% |
2022-06-30 | $8.82M | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | - |
Axsome Therapeutics Revenue Breakdown
Axsome Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 |
---|---|
Royalty | $2.40M |
License | $65.73M |
Product | $202.46M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
---|---|---|---|---|---|---|
Product | $103.74M | $74.10M | $70.75M | $57.13M | $46.02M | $28.57M |
Royalty | $1.03M | $903.00K | $783.00K | $667.00K | $683.00K | $272.00K |
License | - | - | - | $65.73M | $65.73M | - |
Latest
Axsome Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 |
---|---|---|
UNITED STATES | $197.22M | - |
Non-US | $65.73M | $900.00K |
Latest
Quarterly Revenue by Country
Country | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
---|---|---|---|---|---|---|
Non-US | $1.03M | $903.00K | - | $65.73M | $600.00K | $1.70M |
UNITED STATES | $102.81M | $73.27M | $141.44M | $55.78M | - | - |
Latest
Axsome Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
INCY | Incyte | $3.70B | $962.99M |
SRPT | Sarepta Therapeutics | $1.24B | $362.93M |
ACAD | ACADIA Pharmaceuticals | $726.44M | $250.40M |
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
AXSM | Axsome Therapeutics | $270.60M | $87.17M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
TGTX | TG Therapeutics | $233.66M | $83.88M |
MCRB | Seres Therapeutics | $126.33M | - |
VKTX | Viking Therapeutics | - | - |
PDSB | PDS Bio | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
MDGL | Madrigal Pharmaceuticals | - | $62.17M |
TERN | Terns Pharmaceuticals | - | - |
AKRO | Akero Therapeutics | - | - |
HEPA | Hepion Pharmaceuticals | - | - |